ProQR Therapeutics (PRQR) Other financing activities (2013 - 2025)
ProQR Therapeutics (PRQR) posted Other financing activities of $70476.3 for Q1 2025, up 6317.32% sequentially from $1098.2 in Q3 2024, and down 59.95% YoY from $175990.6 in Q1 2024.
ProQR Therapeutics (PRQR) Other financing activities (2013 - 2025) Analysis & Trends
ProQR Therapeutics has reported Other financing activities for 13 years, with the latest figure at $70476.3 in Q1 2025.
- Quarterly Other financing activities fell 59.95% year-over-year to $70476.3 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $260487.7 (down 24.44% YoY) and the FY2021 annual result came in at $1.8 million, up 114.06% from the prior year.
- Other financing activities grew to $70476.3 in Q1 2025 per PRQR's latest filing, from $1098.2 in the prior quarter.
- Over five years, Other financing activities peaked at $686348.3 in Q1 2021 and troughed at $1098.2 in Q3 2024.
- A 5-year average of $205884.7 and a median of $164377.2 in 2023 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2021 and 2024: Other financing activities jumped 132464.32% in 2021, then plunged 99.33% in 2024.
- Over 5 years, Other financing activities stood at $415261.5 in 2021, then plunged by 91.08% to $37037.1 in 2022, then soared by 343.82% to $164377.2 in 2023, then sank by 99.33% to $1098.2 in 2024, then soared by 6317.32% to $70476.3 in 2025.
- According to Business Quant data, Other financing activities over the past three periods registered $70476.3, $1098.2, and $12922.7 for Q1 2025, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 70,476.26 |
| Mar 31, 2025 | 70,476.26 |
| Sep 30, 2024 | 1,098.22 |
| Sep 30, 2024 | 1,098.22 |
| Jun 30, 2024 | 12,922.65 |
| Jun 30, 2024 | 12,922.65 |
| Mar 31, 2024 | 175,990.61 |
| Mar 31, 2024 | 175,990.61 |
| Sep 30, 2023 | 164,377.16 |
| Sep 30, 2023 | 164,377.16 |
| Jun 30, 2023 | 4,355.70 |
| Jun 30, 2023 | 4,355.70 |
| Mar 31, 2022 | 37,037.14 |
| Mar 31, 2022 | 37,037.14 |
| Dec 31, 2021 | 415,261.46 |
| Dec 31, 2021 | 415,261.46 |
| Sep 30, 2021 | 474,073.50 |
| Sep 30, 2021 | 474,073.50 |
| Jun 30, 2021 | 222,790.22 |
| Jun 30, 2021 | 222,790.22 |